homepage-top-section

Financial details of the deal have not been disclosed. This deal is part of Sanofi’s strategy to explore growth opportunities and build a vaccines pipeline. The transaction will

An interleukin-23 (IL-23) inhibitor, Risankizumab is intended to treat patients with Crohn’s disease who have shown insufficient response, lost response or are intolerant to biologic or conventional treatment.

Quell Therapeutics has raised $156m funding through an oversubscribed Series B funding round to advance its multi-modular engineered T regulatory (Treg) cell therapy pipeline and platform. SV Health

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the use of Pfizer and BioNTech’s Covid-19 vaccine, Comirnaty, in children

Health Canada has granted full approval to Janssen Pharmaceutical Companies of Johnson & Johnson’s single-dose Covid-19 vaccine for the disease prevention in people aged 18 years and above.

The first-in-class Trop-2-directed antibody-drug conjugate was approved for use on TNBC patients who have received at least two systemic therapies including one or more for advanced disease. The

This licensing deal will see Sanofi leverage the LinearDesign platform that will lead to the optimisation of mRNA sequences for human therapeutic and preventive uses. Furthermore, this agreement

Pfizer has secured a contract worth $5.29bn from the US government to supply its experimental Covid-19 oral antiviral drug, Paxlovid (PF-07321332; ritonavir). Designed to hinder the SARS-CoV-2-3CL protease

Pfizer has completed the acquisition of all outstanding shares of clinical-stage immuno-oncology firm Trillium Therapeutics in a deal worth about $2.22bn, or $18.50 per share, in cash. The